Sometimes Think-Tanks Should Rethink
The right-wing think-tank, The Manhattan Institute for Policy Research, has put up a study showing the relationship between longevity and “medical innovation” defined as the overall age of drugs being prescribed.
Siting a study prepared by Frank R. Lichtenberg from Columbia University and the National Bureau of Economic Research, the study shows that, surprise, new drugs do increase life expectancy.
Lichtenberg then set out to examine why this “longevity increase gap” exists by measuring the impact of several factors that researchers agree could affect life expectancy. He found that, although some obvious suspects—obesity, smoking, and the incidence of HIV/AIDS—played a role, the most important factor was “medical innovation.”
Specifically, Lichtenberg found that longevity increased the most in those states where access to newer drugs—measured by mean “vintage” (FDA approval year)—in Medicaid and Medicare programs has increased the most. In fact, about two-thirds of the potential increase in longevity—the longevity increase that would have occurred if obesity, income, and other factors had not changed—is attributable to the use of newer drugs. According to his calculations, for every year increase in drug vintage there is about a two-month gain in life expectancy. These represent important findings given the fact that the costs of prescription drugs continue to receive a great deal of attention in the ongoing debate over health-care policy, while their benefits are often overlooked.
Lichtenberg also estimated impacts on productivity and per-capita medical expenditure. He concluded that states adopting medical innovations more rapidly had faster labor productivity growth, conditional on income growth and other factors, perhaps due to reduced absenteeism from chronic medical ailments. He also found that states that use newer drugs did not experience above-average increases in overall medical expenditure, which contradicts the common perception that advances in medical technology inevitably result in increased health-care spending.
I would expect this to be a bit of propaganda attempting to show that big pharma isn’t the global evil everyone seems to think it is. Pharma companies are good and only have your best interests (and sex lives) at heart. Profits? Banish the thought!
But hey, since the graphics the institute put up were a bit dull, I thought I’d go in and do a little paint by numbers.
The paper has two main tables. The first shows the states ranked by life expectancy. I simply colored the chart according to the way the states voted in the 2004 presidential election.
The second table shows increase life expectancy. Here the coloring was a little easier.
Interestingly, as far as I can tell the measurement being used is the vintage of drugs supplied by Medicare and Medicaid. Strange that there would seem to be that big a difference in how federal programs are being operated at the state and local level. Perhaps all those who decry the evils of Medicare shouldn’t look at the evil heartless Federal Government and spend more time looking a little closer to home at how the federal guidelines are implemented.
But it would also seem to me, that those think-tanks fighting the good fight for Republican values shouldn’t use studies showing how much better life is in Democratic states.
I guess I think they should have rethought their article.